Zack Scott

Zack Scott is a General Partner and Co-Head of the healthcare investment team at Norwest Venture Partners. Before joining Norwest, he served as the co-founder and managing partner of Revelation Partners, an investment firm providing shareholder liquidity and growth capital to various healthcare companies. During his tenure at Revelation Partners, he backed several notable companies that achieved public offerings or acquisitions, including iRhythm Technologies and Respicardia, which was later acquired by Zoll Medical. He currently serves as a board director for six medical technology and therapeutics companies, such as Cytovale and Galvanize Therapeutics, and previously held a board seat at Vertos Medical prior to its acquisition by Stryker. Holding a Doctor of Medicine degree, Scott leverages his clinical background to guide his current focus on funding early and late-stage medical technology, digital health, and therapeutics ventures.